Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
1 clinical trials · Condition
◉ Watch Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
| Record | Firm | Date |
|---|---|---|
| Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States (NCT06161051) | Novartis Pharmaceuticals | 2022-10-03 |
Track Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation automatically
Every clearance here is in the API, with alerts when new ones post.